Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRDN-001 in Chronic Thyroid Eye Disease (Phase III, Randomized, Double-masked, Placebo-controlled)
2023-507217-10-00Phase 3Completed
- Sponsor
- Viridian Therapeutics
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) comparing VRDN-001 with Placebo (2 arms). Primary endpoints: Overall Response Rate and Safety: Adverse Events and Serious Adverse Events. Started Apr 2024; status: completed.
02
Drugs
veligrotug
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on 2023-507217-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507217-10-00.